Trial Profile
Phase I/II Trial of Letrozole (Femara) and Sorafenib (Nexavar) in Postmenopausal Women With Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Sorafenib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 17 Nov 2023 Status changed from active, no longer recruiting to completed.
- 03 May 2023 As this study has been recently started recruiting after being discontinued, primary endpoint has changed and focus of this study got shifted to Ar. Hence, the protocol has been amended.
- 03 May 2023 Planned End Date changed from 1 May 2021 to 20 Oct 2028.